1. Home
  2. UL vs GILD Comparison

UL vs GILD Comparison

Compare UL & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unilever PLC

UL

Unilever PLC

HOLD

Current Price

$66.08

Market Cap

153.0B

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$124.79

Market Cap

155.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UL
GILD
Founded
1930
1987
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.0B
155.9B
IPO Year
N/A
1992

Fundamental Metrics

Financial Performance
Metric
UL
GILD
Price
$66.08
$124.79
Analyst Decision
Buy
Analyst Count
0
20
Target Price
N/A
$127.60
AVG Volume (30 Days)
2.8M
6.9M
Earning Date
07-31-2025
02-10-2026
Dividend Yield
3.43%
2.53%
EPS Growth
N/A
6514.05
EPS
3.32
6.42
Revenue
$70,194,950,090.00
$29,087,000,000.00
Revenue This Year
N/A
$3.63
Revenue Next Year
N/A
$3.10
P/E Ratio
$22.17
$19.42
Revenue Growth
N/A
2.79
52 Week Low
$61.11
$88.57
52 Week High
$73.87
$128.70

Technical Indicators

Market Signals
Indicator
UL
GILD
Relative Strength Index (RSI) 64.78 54.46
Support Level $64.95 $118.17
Resistance Level $65.77 $127.41
Average True Range (ATR) 0.84 2.85
MACD 0.29 0.36
Stochastic Oscillator 98.35 70.11

Price Performance

Historical Comparison
UL
GILD

About UL Unilever PLC

Unilever is a diversified beauty, wellbeing, and personal care (44% of 2024 sales by value), homecare (20%), and packaged food (36%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: